Erlotinib hydrochloride

Antibodies and reagents were purchased as follows: mAb-2E9 (Abcam ab8465, RRID: AB_2096462), Anti-EGFR Affibody® Molecule (Abcam ab95116; RRID: AB_11156238), Anti-EGFR (D38B1, Cell Signaling Technology (CST) 4267; RRID: AB_2246311), Anti-Phospho-Akt (Ser473, D9E, CST 4060; RRID: AB_2315049), Anti-beta-Actin Monoclonal Antibody, HRP Conjugated (13E5 CST 5125; RRID: AB_1903890), Anti-Phospho-EGF Receptor (Tyr1068, D7A5 CST 3777; RRID: AB_2096270), Anti-EGFR (R & D Systems, AF231; RRID: AB_355220), Anti-EGFR (phospho Y992, EM-12, Abcam ab81440; RRID: AB_1658463), Anti-mouse IgG-HRP (Jackson ImmunoResearch 715-035-150; RRID: AB_2340770), Anti-rabbit IgG-HRP (Jackson ImmunoResearch 711-035-152; RRID: AB_10015282), Anti goat IgG-HRP (Jackson ImmunoResearch 705-035-147; RRID: AB_2313587), Anti-Rabbit-HRP (Dako P044801, RRID: AB_2617138), Recombinant Murine EGF (Peprotech, 315-09), Recombinant Murine IL-3 (Peprotech, 213-13), Erlotinib Hydrochloride (Biovision, 1558-100), Lapatinib Ditosylate (Biovision, 1642-25), 4% Paraformaldehyde (EM Grade, Electron Microscopy Service (EMS), 157-4), 25% Glutaraldehyde (Grade I, Sigma G5882), FluoSpheres™ (carboxylate modified, 0.1 μm, infrared (715/755), Invitrogen F8799).

Compound 968 was purchased from Calbiochem (Merck Millipore, Darmstadt, Germany). erlotinib hydrochloride was obtained from Biovision Inc. Compound 968, erlotinib, gefitinib, and cisplatin were dissolved in DMSO, and used at the indicated concentrations. Antibodies against β-actin and secondary antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). Mouse monoclonal EGFR antibody was obtained from Becton, Dickinson and Company. Rabbit polyclonal GAC antibody was made in a company. RPMI 1640 Medium (with 300 mg/L L-Glutamine) and Advanced RPMI 1640 Medium (without L-Glutamine) were purchased from GIBICO (Carlsbad, CA, USA). Crystal violet and other analytical grade chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).